Clinical trials: Cardiovascular Outcomes
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Atrial Fibrillation
Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes
Atrial fibrillation is when the heart's two upper chambers (called atria) beat chaotically and irregularly, out of coordination with the two lower chambers (called ventricles) of the heart.
- Trial name
- NCT02964949
- Testing
- Edoxaban
- Where
- 233 sites in Belgium, Bulgaria and 13 more
- Volunteers
- 607 people
- Sponsor
- Daiichi Sankyo
Heart Failure, Congestive
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
This is a prospective, multi-center, randomized, single-blind clinical trial conducted in the United States (US). The objective of the study is to evaluate the safety and efficacy of the HF Pressure Measurement System in reducing…
- Trial name
- CHAMPION (NCT00531661)
- Testing
- HF Pressure Measurement System
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- CardioMEMS
Multiple Myeloma
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM)…
- Trial name
- ABE-DESCART (NCT06154902)
- Testing
- Idecabtagene vicleucel, Not treated
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Aortic Stenosis
An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)
The purpose of this study is to evaluate whether treatment with an investigational drug as compared to placebo will reduce the risk of major cardiovascular events in patients with aortic stenosis.
- Trial name
- NCT00092677
- Testing
- ezetimibe (+) simvastatin
- Volunteers
- 1,873 people
- Sponsor
- Organon and Co
Pressure Ulcers, Venous Ulcers
Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing
The clinical study is designed to assess the effectiveness, safety and non-immunogenicity of fish skin wound dressing extracellular matrix (ECM) in treating chronic wounds.
- Conditions
- Pressure Ulcers, Venous Ulcers, Diabetic Ulcers, Chronic Ulcer of Foot
- Trial name
- NCT01348581
- Testing
- Marigen Wound Dressing
- Where
- Iceland
- Volunteers
- 37 people
- Sponsor
- Kerecis Ltd.
Hereditary Angioedema (HAE)
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
The main aim of this study is to describe the treatment patterns, characteristics and outcomes of people with HAE who are currently receiving icatibant in the homecare setting in the United Kingdom (UK).
- Trial name
- NCT05489640
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 85 people
- Sponsor
- Takeda
Type 2 Diabetes, Cardiovascular Disease
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
- Trial name
- NCT01609582
- Testing
- TAK-875
- Where
- 584 sites in United States, Argentina and 30 more
- Volunteers
- 3,207 people
- Sponsor
- Takeda
Heart Failure
Rheos System for the Treatment of HFpEF Heart Failure
The purpose of this clinical investigation (NCT00957073) is to continue long-term follow-up of device arm subjects enrolled in the HOPE4HF Trial, utilizing the BAROSTIM NEO™ LEGACY device for Implantable Pulse Generator (IPG)…
- Trial name
- HOPE4HF (NCT00957073)
- Testing
- Rheos® system
- Where
- 22 sites in United States
- Volunteers
- 19 people
- Sponsor
- CVRx, Inc.
Myocardial Infarction
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia.
- Trial name
- STREAMLINE (NCT07142265)
- Where
- 18 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38…
- Trial name
- NCT05217082
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Cardiovascular Diseases
A Study of Evacetrapib in High-Risk Vascular Disease
The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
- Trial name
- ACCELERATE (NCT01687998)
- Testing
- Evacetrapib
- Where
- 444 sites in United States, Argentina and 35 more
- Volunteers
- 12,092 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)
The objective of this study is to assess the current standard of care treatment outcome in none/mild, moderate and severely calcified coronary lesions using: A composite of MACE at 30-day and one (1) year post procedure, and…
- Trial name
- MACE (NCT01930214)
- Testing
- Percutaneous Coronary Intervention
- Where
- 34 sites in United States
- Volunteers
- 350 people
- Sponsor
- Abbott Medical Devices
Diabetes Mellitus, Type 2
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease.
- Trial name
- SOUL (NCT03914326)
- Testing
- Semaglutide
- Where
- 492 sites in United States, Algeria and 32 more
- Volunteers
- 9,651 people
- Sponsor
- Novo Nordisk A/S
Myocarditis, Pericarditis
A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
The main goal of this study is to describe the clinical course, outcomes and risk factors for myocarditis and pericarditis associated with Moderna vaccination targeting SARS-CoV-2.
- Trial name
- NCT06113692
- Testing
- mRNA-1273
- Where
- 5 sites in Denmark, Norway and 2 more
- Volunteers
- 1,169 people
- Sponsor
- ModernaTX, Inc.
Acute Pulmonary Embolism (PE), Pulmonary Embolism
Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism Using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
To evaluate the efficacy, safety, and long-term functional outcomes of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for the treatment of acute pulmonary…
- Trial name
- RECOVER-AV (NCT06697314)
- Testing
- AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
- Where
- Poland
- Volunteers
- 256 people
- Sponsor
- Angiodynamics, Inc.
Orthopedic Disorder, Neurologic Disorder
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions.
- Conditions
- Orthopedic Disorder, Neurologic Disorder, Urologic Diseases, Erectile Dysfunction
- Trial name
- NCT03899298
- Testing
- Amniotic and Umbilical Cord Tissue Procedure
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- R3 Stem Cell
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
Coronary Stenosis
The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)
1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. Patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure…
- Trial name
- NCT00403338
- Testing
- CYPHER® Bx Velocity™ stent (sirolimus-eluting)
- Volunteers
- 1,500 people
- Sponsor
- Cordis US Corp.
Chronic Kidney Disease
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.
- Trial name
- Dapa-CKD (NCT03036150)
- Testing
- Dapagliflozin
- Where
- 390 sites in United States, Argentina and 19 more
- Volunteers
- 4,304 people
- Sponsor
- AstraZeneca